Endocrine Updates

The New Steatotic Liver Disease Subclassification and the New MASH-targeted Pharmacotherapy: Resmetirom

By Maria Nikki Cruz, MD Steatotic Liver Disease (SLD) has various etiologies (Figure 1). Metabolic dysfunction-associated steatotic liver disease (MASLD),

Finerenone: New Kid on the Block in Diabetic Kidney Disease

By Julie Anne Gabat-Tan, MD, FPCP, FPCEDM and Gretchen Ang-Manuel, MD, FPCP De La Salle University Medical Center Diabetes is

CHASING SHADOWS: The Search For Clarity

Kayla Pamela dela Cerna, MD; Estherly Grace Gonzales, MD; Aaron Ciel Perez, MD; Bernadette Diane Vista, MD; Oliver Allan C.

ENDOCRINE CROSSWORD: 2024 Diabetes Updates

CROSSWORD Karen Ilagan Vega, FPCP, FPCEDM PLAY THE GAME! https://crosswordlabs.com/view/2024-diabetes-updates Contest Mechanics: 1. Solve the word search puzzle and screen

BEHIND THE MASK

Jessa Marie Chua, MD, Joannalyn Reyes, MD, Joseph Francis Sazon, MD, Dionise Ysabelle V. Bawal, MD, FPCP, FPCEDM The

PCEDM Office
Find Us On The Map

Email Us
sec@endo-society.org.ph

Quick Links

Latest Posts

The New Steatotic Liver Disease Subclassification and the New MASH-targeted Pharmacotherapy: Resmetirom

October 28, 2024

Guess the Word: Crack the Endocrine Enigma!

October 11, 2024

Finerenone: New Kid on the Block in Diabetic Kidney Disease

September 24, 2024

Gallery

What is PCEDM?

The PCEDM is a sub-specialty society of the Philippine College of Physicians, a founding member of the ASEAN Federation of Endocrine Societies, and a member of the International Society of Endocrinology.

Learn More >>